The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 17, 2025
Filed:
Oct. 31, 2023
Applicant:
Antiva Biosciences, Inc., Redwood City, CA (US);
Inventors:
Barry Aldous, Brisbane, CA (US);
Ramakrishna Gadiraju, Brisbane, CA (US);
Ankush Argade, Sunnyvale, CA (US);
Zhengle Zhao, Shanghai, CN;
Siyi Jiang, Shanghai, CN;
Runyan Li, Shanghai, CN;
Chao Liu, Shanghai, CN;
Minyan Liu, Shanghai, CN;
Assignee:
Antiva Biosciences, Inc., Redwood City, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07F 9/36 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 31/675 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); A61K 47/44 (2017.01); A61P 15/02 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07F 9/6561 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 9/0036 (2013.01); A61K 9/06 (2013.01); A61K 9/145 (2013.01); A61K 9/146 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61K 47/44 (2013.01); A61P 15/02 (2018.01); A61P 35/00 (2018.01); A61P 43/00 (2018.01); C07F 9/36 (2013.01); C07F 9/65616 (2013.01);
Abstract
A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.